CN103492877B - 抗-分枝杆菌疫苗接种的功效的确定 - Google Patents

抗-分枝杆菌疫苗接种的功效的确定 Download PDF

Info

Publication number
CN103492877B
CN103492877B CN201180066448.8A CN201180066448A CN103492877B CN 103492877 B CN103492877 B CN 103492877B CN 201180066448 A CN201180066448 A CN 201180066448A CN 103492877 B CN103492877 B CN 103492877B
Authority
CN
China
Prior art keywords
vaccine
cell
immune response
purposes
rbcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180066448.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103492877A (zh
Inventor
C·德塞尔
S·H·E·考夫曼
S·班德曼
L·格罗德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Vakzine Projekt Management GmbH
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Vakzine Projekt Management GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV, Vakzine Projekt Management GmbH filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of CN103492877A publication Critical patent/CN103492877A/zh
Application granted granted Critical
Publication of CN103492877B publication Critical patent/CN103492877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180066448.8A 2010-12-21 2011-12-21 抗-分枝杆菌疫苗接种的功效的确定 Active CN103492877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
US61/425,442 2010-12-21
PCT/EP2011/073609 WO2012085099A1 (en) 2010-12-21 2011-12-21 Determination of the efficacy of an anti-mycobacterial vaccination

Publications (2)

Publication Number Publication Date
CN103492877A CN103492877A (zh) 2014-01-01
CN103492877B true CN103492877B (zh) 2015-04-01

Family

ID=45446021

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180066448.8A Active CN103492877B (zh) 2010-12-21 2011-12-21 抗-分枝杆菌疫苗接种的功效的确定

Country Status (25)

Country Link
US (1) US8906389B2 (xx)
EP (1) EP2656070B9 (xx)
JP (1) JP6055780B2 (xx)
KR (1) KR101882040B1 (xx)
CN (1) CN103492877B (xx)
AU (1) AU2011347266B2 (xx)
BR (1) BR112013015878B1 (xx)
CA (1) CA2822715C (xx)
CU (1) CU20130084A7 (xx)
CY (1) CY1117412T1 (xx)
DK (1) DK2656070T3 (xx)
EA (1) EA029833B9 (xx)
ES (1) ES2569035T3 (xx)
HK (1) HK1192322A1 (xx)
HR (1) HRP20160558T1 (xx)
HU (1) HUE027781T2 (xx)
MX (1) MX345961B (xx)
PL (1) PL2656070T3 (xx)
PT (1) PT2656070E (xx)
RS (1) RS54770B1 (xx)
SG (1) SG191331A1 (xx)
SI (1) SI2656070T1 (xx)
SM (1) SMT201600149B (xx)
UA (2) UA113282C2 (xx)
WO (1) WO2012085099A1 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798762A (zh) * 2003-04-23 2006-07-05 马普科技促进协会 效能提高的结核病疫苗
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
CN101329230A (zh) * 2008-07-14 2008-12-24 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
WO2010046039A1 (en) * 2008-10-20 2010-04-29 University Of Zurich Mycobacterium tuberculosis vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
AU776865B2 (en) * 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
JP2001215224A (ja) * 1999-11-25 2001-08-10 Hitachi Chem Co Ltd 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
SG177402A1 (en) * 2009-06-29 2012-02-28 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798762A (zh) * 2003-04-23 2006-07-05 马普科技促进协会 效能提高的结核病疫苗
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
CN101329230A (zh) * 2008-07-14 2008-12-24 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
WO2010046039A1 (en) * 2008-10-20 2010-04-29 University Of Zurich Mycobacterium tuberculosis vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Th17 cells in mucosal immunity and tissue inflammation;Jay K. Kolls;《Seminars in Immunopathology》;20100225;第32卷(第1期);摘要 *

Also Published As

Publication number Publication date
CY1117412T1 (el) 2017-04-26
KR20140020243A (ko) 2014-02-18
SI2656070T1 (sl) 2016-05-31
HRP20160558T1 (hr) 2016-06-17
SMT201600149B (it) 2016-07-01
EA029833B1 (ru) 2018-05-31
JP2014502841A (ja) 2014-02-06
HK1192322A1 (en) 2014-08-15
BR112013015878A2 (pt) 2016-10-04
MX2013007244A (es) 2014-01-17
SG191331A1 (en) 2013-07-31
US8906389B2 (en) 2014-12-09
EP2656070B9 (en) 2017-01-04
EA029833B9 (ru) 2018-06-29
EP2656070B1 (en) 2016-03-09
EP2656070A1 (en) 2013-10-30
HUE027781T2 (en) 2016-11-28
UA112067C2 (uk) 2016-07-25
US20130280739A1 (en) 2013-10-24
CA2822715A1 (en) 2012-06-28
CU20130084A7 (es) 2013-12-27
ES2569035T3 (es) 2016-05-06
DK2656070T3 (en) 2016-06-13
MX345961B (es) 2017-02-28
RS54770B1 (sr) 2016-10-31
PL2656070T3 (pl) 2017-01-31
KR101882040B1 (ko) 2018-07-25
WO2012085099A1 (en) 2012-06-28
AU2011347266B2 (en) 2016-07-21
UA113282C2 (xx) 2017-01-10
PT2656070E (pt) 2016-06-17
EA201300738A1 (ru) 2013-12-30
CA2822715C (en) 2019-04-30
CN103492877A (zh) 2014-01-01
AU2011347266A1 (en) 2013-07-25
BR112013015878B1 (pt) 2020-10-27
JP6055780B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
US9879268B2 (en) Recombinant Mycobacterium as a vaccine
Rodriguez et al. In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment
CN103492877B (zh) 抗-分枝杆菌疫苗接种的功效的确定
Scordo et al. Recall responses in the lung environment are impacted by age in a pilot study of Mycobacterium bovis-BCG vaccinated rhesus macaques
Sibley et al. High dose aerosol challenge with Mycobacterium tuberculosis fails to overcome BCG vaccination-induced protection in cynomolgus macaques of Chinese origin: implications of natural resistance for TB vaccine evaluation.
Walker et al. Impact of SIV infection on mycobacterial lipid-reactive T cell responses in Bacillus Calmette-Guérin (BCG) inoculated macaques
Dockrell T cell protective immune responses against TB
Govender Development of novel T cell assays and assessment of immune recognition to latency associated M. tuberculosis-specific antigens Rv2660 and Rv2659
Maggioli et al. A manuscript submitted to Frontiers in Immunology
Lutwama Comparison of immune responses induced by Bacillus calmette-Guerin when given at birth or at 6 weeks of age in Ugandan Infants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192322

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192322

Country of ref document: HK